OSCR

Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction.

Overview

Authors: Damijan Knez1, David Malinak2,3, Anže Meden1, Svit Ferjančič Benetik1, Anja Pišlar1, Zuzana Kohoutova2,3, Iveta Vondrackova2,3, Miroslav Psotka2,3, Antonin Lycka3, Lenka Pulkrabkova2, Ondrej Soukup2, Adam Skarka3, Rudolf Andrys3, Xavier Brazzolotto4, Alexandre Igert4, José Dias4, Florian Nachon4, Jan Detka5, Filip Targosiński5, Dziyana Hliabovich5
and 7 other authorsJoseph S Brunzelle6, Ludmilla Shuvalova6, Kinga Sałat5, Saktimayee Mitra Roy6, Daniel Martin Watterson6, Kamil Musílek2,3, Stanislav Gobec1
  1. University of Ljubljana, Faculty of Pharmacy, 1000 Ljubljana, Slovenia
  2. University Hospital in Hradec Kralove, Biomedical Research Centre, 500 05 Hradec Kralove, Czech Republic
  3. University of Hradec Kralove, Faculty of Science, Department of Chemistry, 500 03 Hradec Kralove, Czech Republic
  4. Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge 91220, France
  5. Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow 30-688, Poland
  6. Department of Pharmacology, Northwestern University, Chicago, Illinois 60611, United States
Journal: Journal of medicinal chemistry, volume 69, issue 16, pages 19891-19917
Dates: received 6 May 2026; accepted 24 July 2026; published online 10 August 2026; in print August 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1021/acs.jmedchem.6c01461 · PMID 42679157 · PMCID PMC13528200 · OpenAlex W7202116751
Open access: hybrid, a free copy (OpenAlex)
Categories: human (organism), mouse (organism), cellular / molecular (subfield)
MeSH: Butyrylcholinesterase*, Cholinesterase Inhibitors*, Cognitive Dysfunction*, Mitogen-Activated Protein Kinase 14*, Neuroinflammatory Diseases*, Protein Kinase Inhibitors*, Pyridazines*, Amnesia, Animals, Cognitive Enhancement, Crystallography, X-Ray, Humans, Lipopolysaccharides, Male, Mice, Microglia, Models, Molecular, Structure-Activity Relationship (* major topic)
Topic: Cholinesterase and Neurodegenerative Diseases (Pharmacology (medical), Medicine), according to OpenAlex
Funding: bilateral cooperation gran (BI-FR/23-24-PROTEUS-002); The Slovenian Research and Innovation Agency (N1-0277, P1-0208, P4-0127); Ministarstvo za visoko ?olstvo, znanost in inovacije Republike Slovenije (NA); Univerza v Ljubljani (NA); NIA NIH HHS (AG062095, U01 AG043415, AG043415, R42 AG062095); Univerzita Hradec Králové (2206/2025-2026); National Institute on Aging (AG062095, AG043415); European Regional Development Fund (NA); Ministerstvo Zdravotnictví Ceské Republiky (UHHK, 00179906); Ministère des Armées (NBC-5-C-2316); Narodowe Centrum Nauki (DEC-2021/43/I/NZ7/00342); Grantová Agentura Ceské Republiky (GF23-42701L); Uniwersytet Jagiellonski Collegium Medicum (N42/DBS/000454)
Citations: not cited yet (Europe PMC); 103 references in the paper

Abstract

Chronic neuroinflammation and cholinergic dysfunction are major contributors to cognitive decline in Alzheimer’s disease. Here, we report a series of pyridazine-based multitarget-directed ligands that simultaneously inhibit human butyrylcholinesterase (hBChE) and p38α mitogen-activated protein kinase (p38α MAPK). Pyridazines 8 and 21 were identified as potent dual inhibitors with submicromolar inhibitory potencies against target enzymes and high selectivity over acetylcholinesterase. X-ray crystallographic analyses revealed the experimental binding modes of 8 and 21 in hBChE and p38α MAPK, and identified conserved π–π, π–cation, and hinge region interactions that rationalize dual-target engagement. Both compounds were blood-brain barrier permeable, exhibited low cytotoxicity, and significantly attenuated lipopolysaccharide-induced proinflammatory responses and apoptosis in BV2 microglia. In vivo, compound 21 enhanced cognitive performance in mouse models of scopolamine-induced amnesia and LPS-stimulated neuroinflammatory cognitive impairment. Collectively, these results document the potential of structure-assisted design to achieve selective dual-target pharmacology within a single molecular entity.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 3, 28 September 2026

  • Publisher: n/a → American Chemical Society

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 27 authors, 18 MeSH terms, 13 funders, 102 references.

Cite

This paper

Knez, D., Malinak, D., Meden, A., Ferjančič Benetik, S., Pišlar, A., Kohoutova, Z., Vondrackova, I., Psotka, M., Lycka, A., Pulkrabkova, L., Soukup, O., Skarka, A., Andrys, R., Brazzolotto, X., Igert, A., Dias, J., Nachon, F., Detka, J., Targosiński, F., . . . Gobec, S. (2026). Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction. Journal of medicinal chemistry, 69(16), 19891-19917. https://doi.org/10.1021/acs.jmedchem.6c01461

BibTeX

@article{knez2026dual,
author = {Knez, Damijan and Malinak, David and Meden, Anže and Ferjančič Benetik, Svit and Pišlar, Anja and Kohoutova, Zuzana and Vondrackova, Iveta and Psotka, Miroslav and Lycka, Antonin and Pulkrabkova, Lenka and Soukup, Ondrej and Skarka, Adam and Andrys, Rudolf and Brazzolotto, Xavier and Igert, Alexandre and Dias, José and Nachon, Florian and Detka, Jan and Targosiński, Filip and Hliabovich, Dziyana and Brunzelle, Joseph S and Shuvalova, Ludmilla and Sałat, Kinga and Roy, Saktimayee Mitra and Watterson, Daniel Martin and Musílek, Kamil and Gobec, Stanislav},
title = {{Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction}},
journal = {Journal of medicinal chemistry},
year = {2026},
month = aug,
volume = {69},
number = {16},
pages = {19891--19917},
publisher = {American Chemical Society},
issn = {0022-2623},
doi = {10.1021/acs.jmedchem.6c01461},
url = {https://doi.org/10.1021/acs.jmedchem.6c01461},
pmid = {42679157},
pmcid = {PMC13528200}
}

RIS

TY - JOUR
AU - Knez, Damijan
AU - Malinak, David
AU - Meden, Anže
AU - Ferjančič Benetik, Svit
AU - Pišlar, Anja
AU - Kohoutova, Zuzana
AU - Vondrackova, Iveta
AU - Psotka, Miroslav
AU - Lycka, Antonin
AU - Pulkrabkova, Lenka
AU - Soukup, Ondrej
AU - Skarka, Adam
AU - Andrys, Rudolf
AU - Brazzolotto, Xavier
AU - Igert, Alexandre
AU - Dias, José
AU - Nachon, Florian
AU - Detka, Jan
AU - Targosiński, Filip
AU - Hliabovich, Dziyana
AU - Brunzelle, Joseph S
AU - Shuvalova, Ludmilla
AU - Sałat, Kinga
AU - Roy, Saktimayee Mitra
AU - Watterson, Daniel Martin
AU - Musílek, Kamil
AU - Gobec, Stanislav
TI - Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction
T2 - Journal of medicinal chemistry
J2 - J Med Chem
PY - 2026
DA - 2026/08/01
VL - 69
IS - 16
SP - 19891
EP - 19917
SN - 0022-2623
PB - American Chemical Society
DO - 10.1021/acs.jmedchem.6c01461
UR - https://doi.org/10.1021/acs.jmedchem.6c01461
LA - en
ER -

CSL-JSON

{
"id": "10.1021/acs.jmedchem.6c01461",
"type": "article-journal",
"title": "Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction",
"container-title": "Journal of medicinal chemistry",
"author": [
{
"family": "Knez",
"given": "Damijan"
},
{
"family": "Malinak",
"given": "David"
},
{
"family": "Meden",
"given": "Anže"
},
{
"family": "Ferjančič Benetik",
"given": "Svit"
},
{
"family": "Pišlar",
"given": "Anja"
},
{
"family": "Kohoutova",
"given": "Zuzana"
},
{
"family": "Vondrackova",
"given": "Iveta"
},
{
"family": "Psotka",
"given": "Miroslav"
},
{
"family": "Lycka",
"given": "Antonin"
},
{
"family": "Pulkrabkova",
"given": "Lenka"
},
{
"family": "Soukup",
"given": "Ondrej"
},
{
"family": "Skarka",
"given": "Adam"
},
{
"family": "Andrys",
"given": "Rudolf"
},
{
"family": "Brazzolotto",
"given": "Xavier"
},
{
"family": "Igert",
"given": "Alexandre"
},
{
"family": "Dias",
"given": "José"
},
{
"family": "Nachon",
"given": "Florian"
},
{
"family": "Detka",
"given": "Jan"
},
{
"family": "Targosiński",
"given": "Filip"
},
{
"family": "Hliabovich",
"given": "Dziyana"
},
{
"family": "Brunzelle",
"given": "Joseph S"
},
{
"family": "Shuvalova",
"given": "Ludmilla"
},
{
"family": "Sałat",
"given": "Kinga"
},
{
"family": "Roy",
"given": "Saktimayee Mitra"
},
{
"family": "Watterson",
"given": "Daniel Martin"
},
{
"family": "Musílek",
"given": "Kamil"
},
{
"family": "Gobec",
"given": "Stanislav"
}
],
"container-title-short": "J Med Chem",
"volume": "69",
"issue": "16",
"page": "19891-19917",
"DOI": "10.1021/acs.jmedchem.6c01461",
"PMID": "42679157",
"PMCID": "PMC13528200",
"ISSN": "0022-2623",
"publisher": "American Chemical Society",
"URL": "https://doi.org/10.1021/acs.jmedchem.6c01461",
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
1
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1021/acs.jmedchem.5c00577
Lead Optimization of a Butyrylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease.
Journal: Journal of medicinal chemistry
In common: mouse, 16 references, 4 authors
[2] doi:10.1038/s44321-025-00303-6
Identification of p38 MAPK inhibition as a neuroprotective strategy for combinatorial SMA therapy.
Journal: EMBO molecular medicine
In common: mouse, 7 references, author Daniel Martin Watterson
[3] doi:10.1021/acs.jmedchem.6c01882
Selective Brain-Penetrant TTBK1 Inhibitors Modulate TDP-43 Pathology and Rescue Cognitive Deficits in a Mouse Model of TDP-43 Proteinopathy.
Journal: Journal of medicinal chemistry
In common: mouse, cellular / molecular, 6 references
[4] doi:10.1016/j.celrep.2024.115205 [code]
Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy.
Journal: Cell reports
In common: cellular / molecular, 4 references
[5] doi:10.1186/s12974-025-03680-4
MicroRNA-29a-5p contributes to neuroinflammation through TLR7.
Journal: Journal of neuroinflammation
In common: mouse, cellular / molecular, 4 references
[6] doi:10.1038/s41467-025-66254-1
Structural basis of calcium-dependent C1ql1/BAI3 assemblies in synaptic connectivity.
Journal: Nature communications
In common: mouse, cellular / molecular, 4 references
[7] doi:10.1007/s11357-025-01948-4
Early loss of astrocyte p38α MAPK reduces hippocampal neuroinflammation, enhances synaptic strength, and increases non-synaptic mitochondrial uncoupling in female mice during non-pathological aging.
Journal: GeroScience
In common: mouse, cellular / molecular, 3 references
[8] doi:10.1111/jnc.16274
Nanobodies against the myelin enzyme CNPase as tools for structural and functional studies.
Journal: Journal of neurochemistry
In common: mouse, cellular / molecular, 4 references
[9] doi:10.1002/2211-5463.13422
Structural insights into Charcot-Marie-Tooth disease-linked mutations in human GDAP1.
Journal: FEBS open bio
In common: cellular / molecular, 4 references
[10] doi:10.1038/s41467-024-50771-6
High-affinity agonism at the P2X<sub>7</sub> receptor is mediated by three residues outside the orthosteric pocket.
Journal: Nature communications
In common: cellular / molecular, 4 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.